Clinical Trial Update: Studying Complement Inhibition in Complex Cardiac Surgery [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating complement inhibition with vilobelimab in patients undergoing complex cardiac surgery has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Inflammatory Response Syndrome

Drugs mentioned

• Vilobelimab (vilobelimab)

Snippet

Sponsor: InflaRx GmbH | Conditions: Systemic Inflammatory Response Syndrome, C.Surgical Procedure; Cardiac | Phase 2 | Status: COMPLETED